
De Novo Cell™ is a spinout from the University of Malta registered in Europe. The company is researching a proprietary procedure for the rapid and efficient production of induced pluripotent stem cells (iPSCs) from cord blood mononuclear cells and peripheral blood cells. Conversion rates between 80-90% are obtained in less than a month. The method uses small-molecule inducers and does not require feeder layer support, and the iPSCs produced are free of any genetic modification. De Novo Cell aims to carry out research and advance stem cell technology, with the aim of producing stem cells which…
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.